CRNX
NASDAQCrinetics Pharmaceuticals Inc.
Price$84.85+0.03 (+0.04%)
01:30 PM07:45 PM
News · 26 weeks63+11%
2026-03-012026-08-23
Mix3690d
- Insider12(33%)
- SEC Filings12(33%)
- Other7(19%)
- Earnings3(8%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERChief Financial & Infra. Ofcr. Schilke Tobin was granted 471 shares, increasing direct ownership by 0.60% to 79,427 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- SECCrinetics Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECCrinetics Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- INSIDERPresident & CEO Struthers Richard Scott exercised 19,928 shares at a strike of $20.07, increasing direct ownership by 5% to 424,706 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- SECSEC Form 10-Q filed by Crinetics Pharmaceuticals Inc.10-Q - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECCrinetics Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- PRCrinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAnnounced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the second quarter ended June 30, 2026. Company Announcements and Second Quarter Highlights: On July 6, 2026, Vertex P
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- SECSEC Form DEFM14A filed by Crinetics Pharmaceuticals Inc.DEFM14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form PREM14A filed by Crinetics Pharmaceuticals Inc.PREM14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECCrinetics Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- INSIDERDirector Vivaldi Coelho Rogerio sold $120,000 worth of shares (3,000 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 19,225 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- SECSEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form 8-K filed by Crinetics Pharmaceuticals Inc.8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- PRVertex to Acquire Crinetics Pharmaceuticals- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated ther
- SECSEC Form 144 filed by Crinetics Pharmaceuticals Inc.144 - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- ANALYSTUBS initiated coverage on Crinetics Pharmaceuticals with a new price targetUBS initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $55.00
- PRCrinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Tuesday, August 4 at 4:30 p.m. ET Domestic:1 833-461-5787International:1 585-542-9983Meeting ID:758613006Passcode:214866 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is re
- INSIDERDirector Deardorf Caren was granted 5,925 shares, increasing direct ownership by 36% to 22,225 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Fust Matthew K was granted 5,925 shares, increasing direct ownership by 26% to 28,761 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Nichols Weston was granted 5,925 shares, increasing direct ownership by 36% to 22,225 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
CRNX FAQ
7 questionsWhat does Crinetics Pharmaceuticals Inc. do?
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide...Where does CRNX stock trade?
Crinetics Pharmaceuticals Inc. (CRNX) is listed on NASDAQ.What sector and industry is CRNX in?
Crinetics Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Crinetics Pharmaceuticals Inc. go public?
Crinetics Pharmaceuticals Inc. (CRNX) completed its IPO in 2018.What are analysts saying about CRNX?
Crinetics Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-07-02. Recent price targets cluster around $3600.00.What companies are similar to CRNX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CRNX side-by-side with any of them on Quantisnow.How can I track CRNX on Quantisnow?
Quantisnow aggregates Crinetics Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRNX to receive live email and push alerts on every new disclosure.